SHELL/BIO-BEAN
Shell and bio-bean announce that together they are helping to power some of London’s buses using a biofuel made partly from waste coffee grounds.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005060/en/
The B20 biofuel contains a 20% bio-component which contains part coffee oil. The biofuel is being added to the London bus fuel supply chain and will help to power some of the buses; without need for modification.
Biofuel provides a cleaner, more sustainable energy solution for buses across London’s network by decreasing emissions1 .
“Our Coffee Logs have already become the fuel of choice for households looking for a high-performance, sustainable way to heat their homes – and now, with the support of Shell, bio-bean and Argent Energy have created thousands of litres of coffee-derived B20 biodiesel which will help power London buses for the first time. ” said bio-bean’s founder Arthur Kay. “It’s a great example of what can be done when we start to reimagine waste as an untapped resource.”
The average Londoner drinks 2.3 cups of coffee a day2 which produces over 200,000 tonnes3 of waste a year, much of which would otherwise end in landfill with the potential to emit 126million kg of CO2 4 . bio-bean works to collect some of these waste coffee grounds from high street chains and factories.
The grounds are dried and processed before coffee oil is extracted. bio-bean works with its fuel partner Argent Energy to process this oil into a blended B20 biofuel. 6,000 litres of coffee oil has been produced, which if used as a pure-blend for the bio component and mixed with mineral diesel to form a B20, could help power the equivalent of one London bus for a year5 .
This latest collaboration is part of Shell’s #makethefuture energy relay, which supports entrepreneurs turning bright energy innovations into a positive impact for communities around the world.
Sinead Lynch, Shell UK Country Chair, said: “When it comes to clean energy, we are always looking for the next inventive solution. A good idea can come from anywhere, but with the scale and commitment of Shell, we can help enable true progress. We're pleased to be able to support bio-bean to trial this innovative new energy solution which can help to power buses, keeping Londoners moving around the city - powered in part by their waste coffee grounds.”
bio-bean founder Arthur Kay won Shell LiveWIRE’s Innovation Award in 2013 and the Mayor’s Entrepreneur Programme in 2012 with his ideas about turning coffee waste into fuel. bio-bean has since gone on to produce bio-mass pellets and briquettes called Coffee Logs, before this latest biofuel innovation.
-Ends-
1 TFL.gov.uk
2 Tassimo
3 bio-bean source information
4 https://www.gov.uk/government/publications/greenhouse-gas-reporting-conversion-factors-2017 (calculation 627kg of CO2 per 1000kg of WCG, bio-bean removes 200,000 tonnes)
5 Calculation based on biofuel consumption and bus circulation numbers detailed quoted by TFL.gov.uk.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171119005060/en/
Contact:
Hill+Knowlton Strategies
Francesca Raquet, +44 207 973 4444
Account
Executive
francesca.raquet@hkstrategies.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 22:32:00 CEST | Press release
Successful Transaction Marks Another Milestone in A-CAP’s Soccer Club Portfolio Strategy Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 20:00:00 CEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc
Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom